SRZN Stock Overview
A clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Surrozen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.87 |
| 52 Week High | US$16.19 |
| 52 Week Low | US$4.50 |
| Beta | 0.93 |
| 11 Month Change | 20.68% |
| 3 Month Change | -8.46% |
| 1 Year Change | 31.41% |
| 33 Year Change | -93.90% |
| 5 Year Change | n/a |
| Change since IPO | -94.15% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation
Aug 21
Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?
Jan 03Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?
Jun 19Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely
Feb 12Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim
Oct 06Surrozen GAAP EPS of -$0.40 beats by $0.06
Aug 11Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)
Oct 14Shareholder Returns
| SRZN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | 1.4% | 2.6% |
| 1Y | 31.4% | 23.1% | 30.5% |
Return vs Industry: SRZN exceeded the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: SRZN matched the US Market which returned 30.5% over the past year.
Price Volatility
| SRZN volatility | |
|---|---|
| SRZN Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SRZN's share price has been volatile over the past 3 months.
Volatility Over Time: SRZN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 42 | Craig Parker | www.surrozen.com |
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis.
Surrozen, Inc. Fundamentals Summary
| SRZN fundamental statistics | |
|---|---|
| Market cap | US$26.13m |
| Earnings (TTM) | -US$53.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs SRZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRZN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$27.21m |
| Gross Profit | -US$27.21m |
| Other Expenses | US$26.24m |
| Earnings | -US$53.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SRZN perform over the long term?
See historical performance and comparison